The biochemist and pharmaceutical industry subcontractor Lonza has strengthened its cooperation with the French laboratory Servier in microbial production. In this context, the Basel group will extend its production infrastructure to Visp.
Lonza and the hexagonal pharmaceutical group recently extended their long-term production agreement for the enzyme L-asparaginase, allowing Servier to provide treatments for patients with severe lymphoblastic lymphoma (LLB), a cancer of the blood , Lonza said Tuesday in a statement.
Financial details of the deal were not detailed. This will be the sixth production line to be installed at the Visp Biopark, which is currently under construction. It will be operational in the second half of 2022 and will allow the recruitment of around 100 additional people.